Lorianne Masuoka K. 4
4 · OPIANT PHARMACEUTICALS, INC. · Filed Mar 3, 2023
Insider Transaction Report
Form 4
Lorianne Masuoka K.
Director
Transactions
- Disposition to Issuer
Common Stock
2023-03-02$20.00/sh−2,000$40,000→ 2,000 total - Disposition to Issuer
Common Stock
2023-03-02$20.00/sh−2,000$40,000→ 0 total - Award
Stock Option (right to buy)
2023-03-02−5,000→ 0 totalExercise: $10.80Exp: 2031-03-17→ Common Stock (5,000 underlying)
Footnotes (3)
- [F1]Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Indivior Inc., and Olive Acquisition Subsidiary, Inc., dated as of November 13, 2022 (the "Merger Agreement"), in exchange for a cash payment of $20.00 per share without interest thereon (the "Merger Consideration").
- [F2]Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration. The number of shares disposed of reflects 2,000 shares of Common Stock upon the acceleration of vesting of restricted stock units in accordance with the Merger Agreement.
- [F3]The option was cancelled pursuant to the Merger Agreement in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares.